Hims & Hers Health (HIMS) signed a deal with Eli Lilly (LLY) on Friday to sell the company’s anti-obesity drugs, further consolidating itself in the GLP-1 brand space. Him shares rose 8% to 26, while Lilly shares fell less than 1% to 1,354.49. The deal will allow Hims to sell Lilly’s Zepbound and Foundayo on its telehealth platform. Follow a… Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
